Plasma-derived product · Immune activation, directed at SARS-CoV-2 spike protein · developed by Emergent BioSolutions
COVID-HIG is a purified liquid immunoglobulin G (IgG) preparation derived from human plasma containing anti-SARS-CoV-2 antibodies. It is studied for the treatment of SARS-CoV-2 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05142306 | Phase 1 | SARS-CoV-2 Infection | Completed | EBS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
SARS-CoV-2 Infection
Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.
See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EBS catalysts and pipeline →